Ma Yangguang, Mou Xuanqin, Beeraka Narasimha M, Guo Yuexin, Liu Junqi, Dai Jianrong, Fan Ruitai
Department of Radiation Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
School of Information and Communications Engineering, Xi'AN Jiaotong University, Xi'an 710049, China.
Curr Pharm Des. 2023;29(34):2738-2751. doi: 10.2174/0113816128226519231017050459.
Dose reconstructed based on linear accelerator (linac) log-files is one of the widely used solutions to perform patient-specific quality assurance (QA). However, it has a drawback that the accuracy of log-file is highly dependent on the linac calibration. The objective of the current study is to represent a new practical approach for a patient-specific QA during Volumetric modulated arc therapy (VMAT) using both log-file and calibration errors of linac.
A total of six cases, including two head and neck neoplasms, two lung cancers, and two rectal carcinomas, were selected. The VMAT-based delivery was optimized by the TPS of Pinnacle^3 subsequently, using Elekta Synergy VMAT linac (Elekta Oncology Systems, Crawley, UK), which was equipped with 80 Multi-leaf collimators (MLCs) and the energy of the ray selected at 6 MV. Clinical mode log-file of this linac was used in this study. A series of test fields validate the accuracy of log-file. Then, six plans of test cases were delivered and log-file of each was obtained. The log-file errors were added to the corresponding plans through the house script and the first reconstructed plan was obtained. Later, a series of tests were performed to evaluate the major calibration errors of the linac (dose-rate, gantry angle, MLC leaf position) and the errors were added to the first reconstruction plan to generate the second reconstruction plan. At last, all plans were imported to Pinnacle and recalculated dose distribution on patient CT and ArcCheck phantom (SUN Nuclear). For the former, both target and OAR dose differences between them were compared. For the latter, γ was evaluated by ArcCheck, and subsequently, the surface dose differences between them were performed.
Accuracy of log-file was validated. If error recordings in the log file were only considered, there were four arcs whose proportion of control points with gantry angle errors more than ± 1°larger than 35%. Errors of leaves within ± 0.5 mm were 95% for all arcs. The distinctness of a single control point MU was bigger, but the distinctness of cumulative MU was smaller. The maximum, minimum, and mean doses for all targets were distributed between -6.79E-02-0.42%, -0.38-0.4%, 2.69E-02-8.54E-02% respectively, whereas for all OAR, the maximum and mean dose were distributed between -1.16-2.51%, -1.21-3.12% respectively. For the second reconstructed dose: the maximum, minimum, and mean dose for all targets was distributed between 0.09955.7145%, 0.68924.4727%, 0.58291.8931% separately. Due to OAR, maximum and mean dose distribution was observed between -3.14626.8920%, -6.9899~1.9316%, respectively.
Patient-specific QA based on the log-file could reflect the accuracy of the linac execution plan, which usually has a small influence on dose delivery. When the linac calibration errors were considered, the reconstructed dose was closer to the actual delivery and the developed method was accurate and practical.
基于直线加速器(linac)日志文件重建剂量是用于执行患者特异性质量保证(QA)的广泛使用的解决方案之一。然而,它有一个缺点,即日志文件的准确性高度依赖于直线加速器的校准。本研究的目的是提出一种新的实用方法,用于在容积调强弧形治疗(VMAT)期间使用直线加速器的日志文件和校准误差进行患者特异性QA。
总共选择了6个病例,包括2例头颈部肿瘤、2例肺癌和2例直肠癌。随后,使用Pinnacle^3的治疗计划系统对基于VMAT的放疗进行优化,使用的是配备80个多叶准直器(MLC)且射线能量选择为6MV的医科达Synergy VMAT直线加速器(医科达肿瘤系统公司,英国克劳利)。本研究使用了该直线加速器的临床模式日志文件。通过一系列测试野验证日志文件的准确性。然后,对6个测试病例计划进行照射并获取每个计划的日志文件。通过内部脚本将日志文件误差添加到相应计划中,得到第一个重建计划。随后,进行一系列测试以评估直线加速器的主要校准误差(剂量率、机架角度、MLC叶片位置),并将这些误差添加到第一个重建计划中以生成第二个重建计划。最后,将所有计划导入Pinnacle,并在患者CT和ArcCheck模体(SUN Nuclear)上重新计算剂量分布。对于前者,比较它们之间靶区和危及器官的剂量差异。对于后者,通过ArcCheck评估γ值,随后比较它们之间的表面剂量差异。
验证了日志文件的准确性。如果仅考虑日志文件中的误差记录,有4条弧其机架角度误差超过±1°的控制点比例大于35%。所有弧中叶片在±0.5mm内的误差为95%。单个控制点MU的离散度较大,但累积MU的离散度较小。所有靶区的最大、最小和平均剂量分别分布在-6.79E-02 - 0.42%、-0.38 - 0.4%、2.69E-02 - 8.54E-02%之间,而对于所有危及器官,最大和平均剂量分别分布在-1.16 - 2.51%、-1.21 - 3.12%之间。对于第二个重建剂量:所有靶区的最大、最小和平均剂量分别分布在0.09955.7145%、0.68924.4727%、0.5829~1.